Stroke welcomes Letters to the Editor and will publish them, if suitable, as space permits. They should not exceed 750 words (including references) and may be subject to editing or abridgment. Please submit letters in duplicate, typed double-spaced. Include a fax number for the corresponding author and a completed copyright transfer agreement form (available online at Statin trials have consistently shown a robust (20% to 25%) 1,2 reduction in major vascular events (myocardial infarction, stroke, vascular death), although a previous trial of simvastatin demonstrated no reduction in stroke rate for the subgroup of patients with preexisting cerebrovascular disease. 2 Until recently, the use of statins for secondary stroke prevention in patients without coronary heart disease had not been fully addressed. However, on the basis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial results, 3 statin therapy has been added as Class I B evidence under the new American Heart Association/ American Stroke Association (AHA/ASA) recommendations. 4 In the SPARCL trial of atorvastatin for recent stroke or transient ischemic attack, the use of atorvastatin showed an impressive 16% relative risk reduction (2.2% absolute risk reduction) in subsequent stroke over 5 years. 3 However, the results are tempered because statistical significance was achieved only after prespecified adjustments for geographic region, entry event, gender, and age. At $3.45 per tablet, 5 the cost to prevent a single stroke is $289 628. (Stroke. 2009;40:e41-e42.)
Therefore, when considering the new AHA/ASA recommendations, one must still regard the SPARCL trial results with respect to other new treatments and established therapies (Table) , 2,3,6 -12 many of which are proven more timely and cost effective. The prohibitive cost of atorvastatin may limit its general applicability. 
Sources of Funding

